Achieve Life Sciences Welcomes Dr. Mark Rubinstein as Interim CMO
Dr. Mark Rubinstein Takes the Helm at Achieve Life Sciences
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a prominent player in the specialty pharmaceutical sector, is thrilled to announce that Dr. Mark Rubinstein has stepped into the role of Interim Chief Medical Officer. This exciting transition comes as the company intensifies its commitment to developing cytisinicline, a promising treatment for nicotine dependence, aimed at supporting smoking cessation initiatives.
A New Chapter in Leadership
In his new position, Dr. Rubinstein succeeds Cindy Jacobs, who has played an essential role in guiding the firm through its early stages. Jacobs is anticipated to continue providing invaluable advisory services to support the ongoing journey to provide cytisinicline as an effective option for those battling nicotine addiction.
Dr. Rubinstein's Extensive Background
Bringing a wealth of experience in medical affairs and clinical development, Dr. Rubinstein's career is marked by significant milestones. Before joining Achieve Life Sciences in October 2024, he served as Head of Medical Affairs at Blip, where his innovative strategies helped smokers and vapers quit through evidence-based medications and digital tools. Additionally, his tenure as Vice President of Global Scientific Affairs at Juul Labs showcased his commitment to reducing youth engagement with nicotine products. His academic credentials include being a Professor Emeritus of Pediatrics at the University of California, San Francisco, where his contributions spanned nearly two decades.
Leading the Charge Against Nicotine Dependence
“We are incredibly grateful for Cindy's contributions to Achieve Life Sciences,” stated Rick Stewart, CEO. “Mark’s leadership will be pivotal as we aim to address the pressing public health challenge posed by nicotine addiction.” The company is gearing up for an exciting phase, highlighted by the recent acceptance of their New Drug Application by the FDA for cytisinicline, positioning them for significant progress in their clinical and regulatory agenda.
The Importance of Cytisinicline
Cytisinicline stands out in the pharmaceutical landscape as it targets an urgent need in public health. Approximately 29 million adults in the United States grapple with the challenges of smoking combustible cigarettes, making tobacco use the leading preventable cause of death globally. Annually, millions face health deterioration due to smoking and secondhand smoke exposure. Additionally, the rise of vaping among 17 million adults underscores the necessity for effective cessation aids.
A Bright Future on the Horizon
With a PDUFA completion date set for June 20, 2026, the outlook for cytisinicline as a treatment for smoking cessation is promising. Achieve Life Sciences has not only completed successful Phase 2 studies targeting vaping cessation but has also engaged in productive discussions with the FDA regarding future indications. This progress signals a significant step forward in addressing the critical needs of smokers and vapers alike.
Mechanism of Action of Cytisinicline
This groundbreaking treatment is a plant-derived alkaloid designed to interact with the nicotinic acetylcholine receptors in the brain. By doing so, it aims to mitigate withdrawal symptoms and cravings during the cessation process while also reducing the rewarding sensations associated with nicotine. Although cytisinicline is still in its investigational stages and has not yet garnered FDA approval for any specific indication, its potential is being keenly observed in the medical community.
Frequently Asked Questions
What is the role of Dr. Mark Rubinstein at Achieve Life Sciences?
As the Interim Chief Medical Officer, Dr. Rubinstein is responsible for leading medical affairs and guiding the company's clinical strategies for cytisinicline.
What is cytisinicline?
Cytisinicline is a plant-derived alkaloid being developed as a treatment for nicotine dependence, particularly for smoking and vaping cessation.
How many adults smoke in the United States?
Approximately 29 million adults in the United States smoke combustible cigarettes, highlighting a significant public health issue.
What recent progress has Achieve Life Sciences made?
Achieve recently received FDA acceptance for their cytisinicline New Drug Application, marking a critical advancement in their development timeline.
Who can be contacted for more information about Achieve Life Sciences?
For inquiries, Nicole Jones is the contact person at Achieve Life Sciences and can be reached at 425-686-1510 or via email at ir@achievelifesciences.com.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.